A clinical company ProQR Therapeutics N.V. has recently dosed the first participant in the Phase 1 clinical trial of AX-0811, which is being conducted in Leiden, Netherlands, and Cambridge, Massachusetts. This trial aims to test the RNA editing technology platform known as ADAR-mediated Axiomer™. ProQR is listed on Nasdaq as PRQR and focuses on developing transformative RNA therapies. The trial involves healthy volunteers and marks an important step in their journey to changing lives through innovative medical solutions. This milestone was announced on September 9, 2026.